Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dechra announces “groundbreaking” strangles vaccine
"We are sure that the new strangles vaccine will be a vital tool in disease prevention and a huge benefit to the equestrian industry" - Sara Barker, Dechra.

Protein-based tool is available for horses and ponies.

Dechra Veterinary Products has announced a "groundbreaking" vaccine to protect horses and ponies against strangles.

Developed over 25 years, Strangvac is the first and only intramuscular vaccine for strangles - a highly contagious disease caused by the Streptococcus equi bacterium.

The new vaccine contains recombinant proteins from Streptococcus equi and features DIVA (Differentiating Infected from Vaccinated Animals) capability. It possesses no live bacteria or bacterial DNA, nor will it trigger a positive result in PCR or culture tests.

Strangvac is proven effective in more than 94 per cent of horses, reducing the clinical signs of strangles, including high temperature, coughing. Difficulty swallowing and inappetance. It can be administered to foals from the age of five months, with two injections given at a four-week interval.

The manufacturer states that horses at high risk of Streptococcus equi should be re-vaccinated after two months, such as those in livery. Immunological memory was found in horses following repeated vaccination six months after primary vaccination.

Strangvac has been made possible thanks to more than €20million of funding from the Animal Health Trust and, more recently, the Swedish company Intervacc AB. 

Dr Andrew Waller, chief scientific officer at Intervacc AB, the company that developed the vaccine, comments: “Strangvac is a groundbreaking new vaccine which, alongside good stable management and biosecurity procedures, can play a really important role in improving herd immunity and reducing the number of strangles cases in the equine population, thereby preventing major economic loss to the equestrian industry.”

Sara Barker, equine field support manager at Dechra, added: “Strangles is highly contagious and is one of the most common equine respiratory diseases with an estimated 600 outbreaks each year in the UK alone. Feared by horse owners due to the potential severity of clinical signs and the infectious nature of strangles, we are sure that the new strangles vaccine will be a vital tool in disease prevention and a huge benefit to the equestrian industry as a whole.”

Further information about the vaccine is available from Dechra territory sales managers.

Become a member or log in to add this story to your CPD history

BEVA gives RVNs right to vote

News Story 1
 The British Equine Veterinary Association (BEVA) is to allow its registered veterinary nurse (RVN) members the right to vote.

RVN members will now be able to take part in key decision-making processes and stand for BEVA council.

Marie Rippingale, chair of BEVA's Nurse Committee, said: "I am very proud to be a part of BEVA.

"This change will help to empower nurses to speak up and contribute, but more importantly, it will give them an opportunity to collaborate with other members of the equine veterinary profession to bring about change that is positive for all." 

Click here for more...
News Shorts
Farmer survey to reveal on-farm impact of bluetongue

A nationwide survey has been launched to better understand how the bluetongue virus is affecting UK farms.

Results will inform the support that farmers receive for bluetongue, as well as preparing the livestock industry for the future.

The short online survey is open to all livestock farmers, regardless of whether they've had a confirmed case of bluetongue on their farm. It asks how many animals have been affected, the severity of their clinical signs and how it has impacted farm business.

The survey takes five minutes to complete and is fully anonymous.

It is led by Fiona Lovatt, of Flock Health Limited, and the Ruminant Health & Welfare bluetongue working group, in collaboration with AHDB and the University of Nottingham.

Dr Lovatt says: "We need to find out what level of clinical signs farmers are seeing in their animals, whether they are experiencing mortality with BTV-3 cases, and what their appetite is to vaccinate in future for bluetongue serotype 3."

The survey can be found here.